IMRT combine with cisplatin concurrent chemotherapy

DRUG4 trials

Sponsors

Zhao Chong, Sun Yat-sen University, Biotech Pharmaceutical Co., Ltd.

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)Head and Neck CancerLocal Advanced High Risk Nasopharyngeal Carcinoma

Phase 2

Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer

RecruitingNCT07751055

Sun Yat-sen UniversityEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2026-08-01End: 2030-12-31Target: 51Updated: 2026-08-07

Phase 3

Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

CompletedNCT02143388

Zhao ChongLocal Advanced High Risk Nasopharyngeal Carcinoma

Start: 2014-03-31End: 2022-08-05Updated: 2022-08-31

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

CompletedNCT02973386

Sun Yat-sen UniversityLocal Advanced High Risk Nasopharyngeal Carcinoma

Start: 2017-01-13End: 2025-12-01Updated: 2026-05-07

Phase 4

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruitingNCT06879691

Biotech Pharmaceutical Co., Ltd.Head and Neck Cancer

Start: 2021-05-15End: 2025-04-14Target: 171Updated: 2025-03-17

Related Papers

Survival and pain treatment de-escalation of concurrent chemoradiotherapy combined with nimotuzumab and analgesics for patients with advanced head and neck cancer: A randomized, controlled clinical study.

Journal of Clinical Oncology2026-05-28

Treatment response-adapted risk index model for survival prediction and adjuvant chemotherapy selection in nonmetastatic nasopharyngeal carcinoma

npj Digital Medicine2025-09-01

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

JAMA Oncology2022-10-1365 citations

Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.

Journal of Clinical Oncology2021-05-2021 citations